Society of interventional radiology critique and commentary on the cochrane report on transarterial chemoembolization

Hepatology

Volumn 57, Issue 4, 2013, Pages 1675-1676

  Rose, Steven C ^a   Kikolski, Steven G ^a   Gish, Robert G ^b   Kono, Yuko ^b   Loomba, Rohit ^b   Hemming, Alan W ^c   Wallace, Michael J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETHIODIZED OIL; SORAFENIB;

ABLATION THERAPY; ARTERY OCCLUSION; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; EVIDENCE BASED MEDICINE; HEPATIC ARTERY; HUMAN; INTERVENTIONAL RADIOLOGY; ISCHEMIA; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 84876120503     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26000     Document Type: Letter

References (14)

1. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable carcinoma. The Cochrane Collaboration. Hoboken, NJ: Wiley; 2011: 1-56.
2. Bruix J, Llovet JM, Castells, Montañá X, Bru C, Ayuso MC, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. HEPATOLOGY 1998; 27: 1578-1583.
3. Llovet JM, Real MI, Montañá X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symtomatic treatment in patients with unresectable hepatocellular carcinoma: a radomised controlled trial. Lancet 2002; 359: 1734-1739.
4. Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004; 24: 625-629.
5. Li JQ, Zhang YQ, Zhang WZ, Yuan YF, Li GH. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 1995; 121: 364-366.
6. Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg 2006; 23: 235-240.
7. Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis-a randomized study. World J Surg 2006; 30: 2004-11.
8. Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. Chin Med J 2003; 116: 203-207.
9. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184.
10. Trinchet JC, Rached AA, Beaugrand M, et al. Groupe D'Etude Et De Traitement Du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261.
11. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129-134.
12. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. HEPATOLOGY 2002; 35; 1164-1171.
13. Doffoël M, Bonnetain F, Bouché O, et al. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Eur J Cancer 2008; 44: 528-538.
14. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.